Summer 2025
Data Scientist Intern
Posted on 2/7/2025
Cardiosense
11-50 employees
Non-invasive cardiac monitoring with AI analytics
No salary listed
Chicago, IL, USA
In Person
 Data & Analytics (1) |
|---|
Get referred to Cardiosense
Find people who can refer or advise you
- Bachelors in Electrical Engineering, Computer Science, Statistics, Mathematics, or related fields. Master’s or PhD student/graduate preferred.
- 2+ years of experience in the field of data science or machine learning with a focus on biomedical applications.
- Expertise in programming languages such as Python, R, or Scala.
- Exposure to machine learning frameworks (TensorFlow, PyTorch, Scikit-learn).
- Strong analytical thinking and problem-solving abilities.
- Excellent communication and presentation skills.
- Proven ability to influence cross-functional teams and stakeholders.
- Collaborate with cross-functional teams to identify opportunities for leveraging company data to develop machine learning solutions.
- Collaborate with clinical teams and external vendors to facilitate data collection.
- Design, develop, and deploy scalable machine learning models and advanced analytics.
- Apply digital signal processing techniques to physiological waveforms (PPG, ECG, SCG, etc.) and build novel machine learning algorithms for hemodynamic assessment.
- Optimize existing algorithms and pipelines to improve efficiency and performance.
- Perform exploratory data analysis to extract actionable insights.
- Develop predictive, prescriptive, and descriptive analytics to inform decision-making.
- Work with structured and unstructured data to uncover trends and patterns.
- Partner with data engineering teams to ensure the availability of robust data pipelines.
- Recommend and implement data tools, frameworks, and platforms to enhance workflows.
- Communicate findings and recommendations to technical and non-technical stakeholders.
- Master’s or PhD student/graduate preferred.
Cardiosense develops a non-invasive cardiac monitoring platform that uses wearable biometric sensors and artificial intelligence to analyze the full electromechanical behavior of each heartbeat. The system continuously tracks heart electrical signals and mechanical activity to provide early warnings of declining heart function. By selling the devices and offering a subscription-based analytics platform, Cardiosense targets hospitals and clinics to help healthcare teams prioritize at-risk patients and enable proactive interventions. Unlike traditional monitoring that relies on invasive methods or single-signal data, Cardiosense combines multiple data streams and AI-driven insights to detect signs of deterioration before symptoms appear. The company aims to improve patient outcomes by enabling timely care while the technology remains investigational under U.S. law.
Company Size
11-50
Company Stage
Series A
Total Funding
$15.1M
Headquarters
Chicago, Illinois
Founded
2020
Get referred to Cardiosense
Find people who can refer or advise you
Simplify's Take
What believers are saying
- Adult HFrEF is a clear initial market with urgent monitoring needs.
- Hospitals can use earlier fluid detection to intervene before decompensation.
- Multi-sensor data and partnerships support expansion beyond heart-failure monitoring.
What critics are saying
- Reimbursement delays can block hospital adoption and prolong pilot-only deployments.
- Incumbents like Medtronic and Abbott can bundle competing monitoring solutions.
- Signal noise or drift can undermine trust in noninvasive clinical measurements.
What makes Cardiosense unique
- Physiological waveform AI turns raw biosignals into predictive cardiac biomarkers.
- CardioTag provides noninvasive monitoring versus catheter-based pressure measurement.
- Breakthrough and De Novo regulatory milestones strengthen clinical credibility.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Relocation Assistance
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 8%2 year growth
↑ 8%Cardiosense Receives $15.1M Series A Round Back to HomeCHICAGO, IL, Cardiosense announced that it has raised $15.1 million in Series A funding.Cardiosense, a digital health company leveraging artificial intelligence and multi-sensor devices to enable early detection of cardiovascular disease, announced today that it has raised $15.1 million in Series A funding, co-led by Broadview Ventures and Hatteras Venture Partners, with participation from Laerdal Million Lives Fund, OSF Ventures, UnityPoint Health Ventures, and Portal Innovations. The capital will be used to support team expansion, accelerate product development, and fund an expansive heart failure study.Cardiosense is building a physiological waveform AI platform to develop predictive biomarkers to detect and manage cardiac disease. The Company has developed a suite of novel digital tools, multi-sensor devices, and analysis algorithms to detect early signs of cardiovascular disease, inform personalized therapy, and improve patient outcomes.(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page